Acrivon Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own13.35% Shs Outstand20.86M Perf Week-0.08%
Market Cap260.75M Forward P/E- EPS next Y- Insider Trans136.09% Shs Float15.07M Perf Month-
Income- PEG- EPS next Q- Inst Own14.42% Short Float / Ratio- / - Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Interest- Perf Half Y-
Book/sh-20.67 P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range10.90 - 20.70 Perf YTD-24.88%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-39.62% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low14.67% ATR3.03
Employees35 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)- Volatility13.39% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.00 Prev Close12.50
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume164.65K Price12.50
Recom- SMA20-10.67% SMA50-10.67% SMA200-10.67% Volume0 Change0.00%
Nov-14-22 10:16PM
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing precision oncology medicines. Its oncology medicines match to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3). The AP3 platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 in a Phase 2 trial across various tumor types. It is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1 and PKMYT1. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorNov 17Buy12.503,389,50042,368,7504,384,206Nov 21 04:31 PM
Chione Ltd10% OwnerNov 17Buy12.50400,0005,000,0003,856,597Nov 21 06:26 PM